Clinical trial Recruiting at 1 site Observational Ages 18 and up Women only

Monitoring blood glucose in pregnant women receiving betamethasone for fetal lung development

Official title: Blood Glucose Levels in Pregnant Non-diabetic Women During Treatment With Betamethasone for Fetal Lung Maturation

Run by University of Aarhus · NCT06794307 · Data updated 2026-11-12

This study looks at how the medication betamethasone affects blood sugar levels in pregnant women who don't have diabetes but are at risk of preterm birth.

More Preterm Birth trials

Quick facts

Study typeObservational
Ages18 Years and up
SexWomen only
Enrollment25 (estimated)
SponsorUniversity of Aarhus
Academic / other
Locations1 site (Aarhus, Central Region Denmark)
StatusRecruiting
StartedNovember 20, 2024
Main results expectedOctober 30, 2025
Study endsJanuary 2026
Registry record updatedJanuary 27, 2025
Trial IDNCT06794307 on ClinicalTrials.gov

Is this trial a fit for you?

Likely a good fit

Ideal candidates for this study are pregnant women between 24 and 34 weeks of gestation who are experiencing symptoms of threatened preterm birth and are planned to receive betamethasone.

Probably not a fit

Patients with diabetes or those on medications affecting glucose metabolism will not benefit from this study.

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This observational study aims to investigate the changes in maternal blood glucose levels in non-diabetic pregnant women receiving betamethasone for fetal lung maturation during threatened preterm birth. Participants will be monitored using continuous glucose monitoring (CGM) to assess glycemic responses over a period of six days. Blood samples will also be collected to measure various metabolic markers, providing a comprehensive understanding of how betamethasone affects glucose homeostasis in this population. The study seeks to fill the knowledge gap regarding the effects of corticosteroids on non-diabetic pregnant women, which has been less explored compared to diabetic counterparts.

Why it matters

Potential benefit: If successful, this study could lead to improved management of blood glucose levels in pregnant women receiving betamethasone, potentially enhancing neonatal outcomes.

How similar studies have gone: While studies have shown the effects of betamethasone in diabetic pregnant women, this specific investigation in non-diabetic women is novel and has not been extensively tested.

Who can join: the full rules

Show full inclusion / exclusion criteria
Inclusion Criteria:

* Pregnant in gestational week 24+0 - 34+0 admitted with symptoms of threatened preterm birth:

  * Premature contractions and shortening of the cervix, or
  * Preterm premature rupture of membranes.
* Treatment with betamethasone for fetal lung maturation is planned, or started (maximum 4 hours before inclusion)
* Age over 18 years
* Read and understand Danish

Exclusion Criteria:

* Multiple pregnancy
* Diabetes
* Pre-existing maternal use of medications that affect glucose metabolism

Where it's running

  • Aarhus University Hospital
    Aarhus, Central Region Denmark, Denmark
    Recruiting

Study contacts

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

How to take part

  1. Review the eligibility criteria above with your treating physician.
  2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
  3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.
Last reviewed 2026-11-14 by the Find a Trial editorial team. Information on this page is for educational purposes and is not medical advice. Always consult qualified healthcare professionals about clinical trial participation.